Parenteral n–3 PUFA supplementation aids in recovery of CD patients after bowel resection
23 Apr 2024
Parenteral supplementation with n‒3 polyunsaturated fatty acids (PUFAs) helps in the recovery of patients with Crohn’s disease (CD) following bowel resection, reports a study. This intervention is also safe, as shown by the fewer complications and reduced inflammatory cytokines.
Indications/Uses : Treatment of infections due to susceptible organisms including UTI, skin & resp tract infections eg, severe nosocomial pneumonia infections caused by multi-resistant microorganisms.
Indications/Uses : Treatment of infections due to susceptible organisms including UTI, skin & resp tract infections eg, severe nosocomial pneumonia infections caused by multi-resistant microorganisms.
Indications/Uses : Treatment of conditions for which corticosteroid therapy is indicated except adrenocortical-deficiency states, for which hydrocortisone w/ supplementary fludrocortisone is preferred.
Indications/Uses : Treatment of conditions for which corticosteroid therapy is indicated except adrenocortical-deficiency states, for which hydrocortisone w/ supplementary fludrocortisone is preferred.
Indications/Uses : Monotherapy or in combination w/ other medicinal products for the treatment of type 2 DM. Prevention of new or worsening heart failure or CV death; nephropathy. Heart failure w/ reduced ejection fracture in adults. CKD in adults.
Indications/Uses : Prevention of VTE in adults who have undergone elective hip or knee replacement surgery; stroke & systemic embolism in adults w/ non-valvular atrial fibrillation (NVAF), w/ ≥1 risk factors, eg, prior stroke or transient ischaemic attack (TIA); ≥75 yr; HTN; DM; symptomatic heart failure (NYHA Class ≥II). Treatment of DVT & pulmonary embolism (PE), & prevention of recurrent DVT & PE in adults.
Contents : Per Norpriexia FC tab Paracetamol 450 mg, orphenadrine citrate 35 mg. Per Norpriexia Forte FC tab Paracetamol 650 mg, orphenadrine citrate 35 mg
Indications/Uses : Short term treatment of moderate pain, particularly after surgery & fever. Relieve pain due to skeletal muscle spasm. Musculoskeletal & joint disorders.
Contents : Per Norpriexia FC tab Paracetamol 450 mg, orphenadrine citrate 35 mg. Per Norpriexia Forte FC tab Paracetamol 650 mg, orphenadrine citrate 35 mg
Indications/Uses : Short term treatment of moderate pain, particularly after surgery & fever. Relieve pain due to skeletal muscle spasm. Musculoskeletal & joint disorders.
Indications/Uses : Treatment of essential HTN. Replacement therapy in patients receiving telmisartan & amlodipine besilate. Add on therapy in patients whose BP is not adequately controlled on telmisartan or amlodipine monotherapy. Initial therapy in patients who are likely to need multiple drugs to achieve BP goals.
Indications/Uses : Treatment of essential HTN. Replacement therapy in patients receiving telmisartan & amlodipine besilate. Add on therapy in patients whose BP is not adequately controlled on telmisartan or amlodipine monotherapy. Initial therapy in patients who are likely to need multiple drugs to achieve BP goals.
Indications/Uses : Julitam Tab: Monotherapy & adjunctive treatment of partial seizures w/ or w/o secondary generalization. Adjunctive therapy of myoclonic seizures & primarily generalized tonic-clonic seizures. Oral soln: Monotherapy in treatment of partial onset seizures w/ or w/o secondary generalisation in patients from 16 yr w/ newly diagnosed epilepsy. Adjunctive therapy in treatment of partial onset seizures w/ or w/o secondary generalisation in adults & childn from 1 mth w/ epilepsy; myoclonic seizures in adults & adolescents from 12 yr w/ juvenile myoclonic epilepsy; primary generalised tonic-clonic seizures in adults & adolescents from 12 yr w/ idiopathic generalised epilepsy. Julitam I.V. Monotherapy in the treatment of partial onset seizures w/ or w/o secondary generalization in adult & adolescent from 16 yr. As adjunctive therapy in the treatment of partial onset seizures w/ or w/o secondary generalization in adult & childn from 4 yr; treatment of myoclonic seizures in adult & adolescent from 12 yr w/ juvenile myoclonic epilepsy; treatment of primary generalized tonic-clonic seizures in adult & adolescent from 12 yr w/ idiopathic generalized epilepsy.
Indications/Uses : Gastric
ulcer. Improvement
of gastric mucosa lesion (erosion, flare & edema) of the following diseases: Acute
gastritis, acute aggravated period of chronic gastritis.
Indications/Uses : Gastric
ulcer. Improvement
of gastric mucosa lesion (erosion, flare & edema) of the following diseases: Acute
gastritis, acute aggravated period of chronic gastritis.